Paolo Tarantino: A Bridge Between Chemotherapy of the Past and the Biological Therapies of the Present

Paolo Tarantino shared on X:

“Conjugated Antibodies: A Bridge Between Chemotherapy of the Past and the Biological Therapies of the Present, Which Gives Thousands of Cancer Patients a Future Every Year. An Honor to Have the Opportunity to Talk to Daniela Cipolloni of Presa Diretta.

Link to the Service.”

Proceed to the video attached to the post.
Source: Paolo Tarantino/X

More posts featuring Paolo Tarantino on oncodaily.com

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.